AHFS Drug Information 2019 : American Hospital Formulary Service Drug Information (2019. 3840 S. 219 x 276 mm)

個数:

AHFS Drug Information 2019 : American Hospital Formulary Service Drug Information (2019. 3840 S. 219 x 276 mm)

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6~9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版
  • 商品コード 9783769274189

Description


(Text)

Protect the patients and practice with the most comprehensive, authoritative drug information.

AHFS is the only drug information resource curated by a not-for-profit scientific organization and the only remaining original federal compendium whose authority for establishing accepted medical uses includes the broadest scope of drugs and indications under Medicaid, Medicare Part D, and more. The 2019 edition is backed by over 60 years of in-depth, unbiased drug coverage-delivering authoritative data for compendia, citations, compliance and more.

Information on prescription, OTC, ophthalmic, and dermatologic drugs is evidence-based, reviewed by subject matter experts, and supported by nearly 90,000 references. Every year's edition is updated with an expanded number of monographs, which can be found on the For Subscribers section with the password found in the preface of each new edition.
It includes therapeutic recommendations supported by primary research, extensive dosage and administration information, extensive off-label uses and related dosing options.

Updates for this edition include:
- Expanded and revised content throughout, featuring critical new monograph updates every year
- Important updated monographs and references related to revised therapeutic guidelines, including revised recommendations for treatment of fungal infections (such as Candida auris infections) and chronic hepatitis C
- Newly published information on breakthrough oncology drugs approved as part of the FDA's accelerated approval program
- Dedicated coverage to orphan products
- Interactions, adverse reactions, and cautions, including ongoing revisions addressing opiate safety issues and their role in pain management
- Therapeutic recommendations supported by evidence from primary research
- Extensive dosage and administration information
- Pharmacology and pharmacokinetics
- Prescription, OTC, ophthalmic and dermatologic drugs
- Extensive off-label uses and related dosing options
- Vaccines and other immunizing agents

Drug monographs in AHFS DI are thoroughly researched by drug information pharmacists and professional editorial and analytical staff. Authors incorporate clinical research findings, guidelines, and FDA-approved labeling into the monographs. The information also reflects the expertise of leading medical scientists, physicians, pharmacists, pharmacologists, and other clinicians, and incorporates the latest therapeutic recommendations from groups like the US Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the American Academy of Pediatrics, the American Heart Association, and many others.

最近チェックした商品